Loading…
MIRA
MIRA Pharmaceuticals Inc
NASDAQ· Healthcare· Drug Manufacturers - General· CUSIP 60458C104
$0.75-2.60%Price as of Aug 29, 18:46 UTC · updated once a day, after the close
Key metrics
- Market cap
- $31.52M
- P/E
- —
- Forward P/E
- —
- P/B
- 3.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.19
- ROE
- -217.12%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.55
- 52-week high
- $2.45
- 52-week low
- $0.60
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -85.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $1.51 | $1.14 | $1.05 | |
| P/B | 6.1x | 6.1x | 8.7x | 3.5x |
| EPS | -$1.35 | -$0.51 | -$0.85 | |
| ROE | -273.92% | -100.49% | -356.98% | -273.92% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SCLXScilex Holding Co | $4.49 | — | — | — | — | $31.59M |
| TELATELA Bio, Inc. | $0.70 | — | — | — | — | $31.43M |
| NNVCNanoviricides Inc | $1.24 | — | 2.9x | — | -89.97% | $31.65M |
| ATNMActinium Pharmaceuticals, Inc. | $1.01 |
About the company
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
- Miami, United States
Company description provided by Yahoo Finance.